United States-based Inovio Pharmaceuticals has dosed the first participant with PENNVAX-GP in a randomised clinical trial that will evaluate its ability to drive remission of HIV infection, it was reported yesterday.
This vaccine targets all major HIV strains and focuses on improving the capacity of the immune system to eliminate or provide life-long control of HIV. This trial is part of a USD6.95m grant from the NIH's National Institute of Allergy and Infectious Diseases (NIAID) to produce a therapy using the company's PENNVAX-GP.
This Phase 1/2 HIV trial is a randomized, double-blinded, placebo-controlled study. The trial is divided into two cohorts, with all vaccines delivered through the CELLECTRA device.
Inovio president and CEO, Joseph Kim, said, 'We have already demonstrated that PENNVAX-GP generated the highest overall levels of T cell and antibody immune response rates ever demonstrated by an HIV vaccine in healthy volunteers. Here, we are going after the Holy Grail of HIV treatment – investigating if our vaccine used alone or in combination with other therapies could bring true remission of HIV in patients. The key to this trial is that T cells generated by our vaccines target the body's HIV reservoirs where the infection 'hides' from antiretroviral therapy. Inovio has already shown (in an HPV therapeutics trial) that our immunotherapy can generate sustained T cell responses which are able to traffic to an immunosuppressive tissue environment and eliminate virus-expressing cells. We expect results from this breakthrough study in late 2019.'
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary